■Lunit announced on the 19th that more than 200 medical institutions in the United States have adopted its breast cancer diagnostic AI solutions, "Lunit Insight MMG" and "Lunit Insight DBT." Lunit is quickly establishing itself in the local market by leveraging Volpara's strong sales network in the U.S. Currently, approximately 400 radiologists across the country are utilizing Lunit's AI solutions, and Lunit and Volpara are supporting over 1 million breast imaging analyses annually in North America. Notably, they have secured key clients, including "Rezolute," which operates over 40 imaging centers nationwide, the largest private outpatient radiology network, "SimonMed Imaging," and the representative university hospital network in the western U.S., "UC Davis Health," thereby expanding their influence in the North American market.
■Yuhan Corporation announced on the 19th that it held the "3rd Yuhan Innovation Program (YIP) Networking Day" event at its headquarters on the 16th. Since 2022, Yuhan Corporation has been running the "Yuhan Innovation Program (YIP)," which supports basic research for innovative drug development. The "Yuhan Innovation Program (YIP)" is an open innovation model specialized in basic research. It supports basic research based on the creative and innovative ideas of researchers in basic sciences affiliated with domestic universities and public research institutions, with follow-up collaborations with Yuhan Corporation occurring based on research results. This event was organized to explore the possibility of innovation drug R&D information exchange and research collaboration between Yuhan Corporation's researchers and YIP researchers.
■KOLON Life Science announced on the 19th that it presented the preclinical results of the anticancer drug candidate "KLS-3021" for cutaneous squamous cell carcinoma (cSCC) at the "2025 American Society of Gene & Cell Therapy (ASGCT)" held in New Orleans from the 13th to the 17th (local time). According to the presentation, KLS-3021 demonstrated high selective cytotoxicity compared to normal human epidermal keratinocytes in human cutaneous squamous cell carcinoma cell lines, while vigorously replicating within tumor cells to effectively kill cancer cells. In efficacy evaluations using Tumor Model 1, the tumor completely disappeared with just one injection, and there were therapeutic effects not only on the primary tumor but also on adjacent lymph nodes in metastatic tumor models. KLS-3021 is a vaccinia virus-based oncolytic virus therapy that enhances cancer cell selectivity. It is characterized by carrying PH-20, Interleukin-12 (IL-12), and sPD1-Fc genes to maximize antitumor effects.
■Dong-A Pharmaceutical announced on the 19th that its inner beauty brand "ILO" has selected Red Velvet's "Irene" as its brand model and unveiled a new advertising campaign titled "Real Red." ILO is a premium inner beauty brand of Dong-A Pharmaceutical that aims for a healthy and self-directed lifestyle under the brand philosophy of "the me I want to be." Selected as the advertising model, "Irene" is an artist loved by the public for her confident and sophisticated image, aligning with the brand image that ILO seeks. This advertising campaign focuses on emphasizing healthy dieting, targeting women aged 25 to 35 who are interested in maintaining a healthy body shape, moving away from messages centered on efficacy and functional effects.
■GeoYoung announced on the 19th that it operated a visit program to its Incheon Smart Hub Center as part of the industrial facility tour program of the "2025 Hospital Pharmacy Department Mid-Level Management Capacity Building Training" organized by the Korean Hospital Pharmacists Association. This tour of GeoYoung by the Korean Hospital Pharmacists Association was designed for mid-level hospital pharmacists working on-site to gain a deeper understanding of the distribution structure of pharmaceuticals related to on-site pharmacy work while touring actual industrial sites and expanding their insights into practical work. GeoYoung conducted the company and Smart Hub Center introduction, technical explanations of key equipment, and a tour of the center in sequence during the field tour program held on the afternoon of the 16th.
■SolDoc, a telemedicine solution corporation, announced on the 19th that it has signed a business agreement with WELT, a leading digital therapeutics company in Korea, regarding the prescription of telemedicine-based digital therapeutics (DTx) and remote health management systems. Accordingly, healthcare professionals can use SolDoc's digital ERP solution, "SolDoc Partners," to easily prescribe WELT's digital therapeutics, "SleepQ," to patients without face-to-face interaction and utilize features such as one-stop payment, appointment scheduling, and data management. As it is the first case of providing a service optimized for tele-prescribing digital therapeutics and patient management in Korea, a plan is in place to present standards to healthcare professionals to utilize rapidly growing DTx and related medical solutions.